ALX Oncology to Present at 2026 Jefferies Global Healthcare Conference, Highlighting Oncology Pipeline

ALX Oncology to Present at 2026 Jefferies Global Healthcare Conference, Highlighting Oncology Pipeline

ALX Oncology is set to present its oncology pipeline at the 2026 Jefferies Global Healthcare Conference in New York. The presentation, scheduled for June 3rd, will feature a fireside chat format and will be webcast live. For investors and business development teams tracking clinical-stage oncology assets, the event offers a timely checkpoint on the company's lead immuno-oncology candidate evorpacept and its EGFR-targeted antibody-drug conjugate ALX2004 — both central to ALX Oncology's value proposition as a Nasdaq-listed biotech navigating a competitive cancer therapy market.

Key Takeaways

• Fireside chat on June 3, 2026: ALX Oncology leadership will present at the 2026 Jefferies Global Healthcare Conference in New York on June 3rd at 5:30 PM ET in a fireside chat format, with a live webcast available through the company's Investors page.
• 90-day replay window: A replay of the webcast will be archived for up to 90 days following the presentation, giving extended access to institutional investors and analysts who cannot attend live.
• Pipeline focus: The presentation is expected to center on evorpacept — the company's lead immuno-oncology candidate — and ALX2004, a novel EGFR-targeted antibody-drug conjugate currently in Phase 1 dose-escalation trials.
• Conference context: The Jefferies Global Healthcare Conference runs June 2–4, 2026, in New York, drawing institutional investors, biotech executives, and BD professionals evaluating life science opportunities.

ALX Oncology's Presentation Details

ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage biotechnology company, announced that its leadership will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York. The session is scheduled for June 3, 2026, at 5:30 PM ET.

A live webcast of the presentation will be accessible by visiting the Investors section of ALX Oncology's website. A replay will be archived for up to 90 days following the event, providing a window for global investors and analysts to review management's remarks and any pipeline updates shared during the discussion.

The conference itself runs from June 2 to June 4, 2026, in New York, and is one of the marquee institutional healthcare investor events on the calendar. It draws senior leadership from publicly traded biotech and pharma companies, making it a consequential venue for ALX Oncology to communicate its clinical progress and strategic direction to a concentrated audience of capital allocators and potential partners.

Pipeline Update: Evorpacept and ALX2004

ALX Oncology's lead therapeutic candidate, evorpacept, has been positioned as a potential cornerstone therapy in immuno-oncology. The compound is currently being evaluated across multiple ongoing clinical trials spanning a wide range of cancer indications. For analysts and BD teams, the Jefferies fireside chat represents an opportunity to gauge whether the company has generated new clinical data or identified specific indications where evorpacept could differentiate from existing CD47-targeting approaches — a class that has faced both clinical and regulatory scrutiny in recent years.

The company's second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1 dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. EGFR remains one of the most heavily validated oncology targets, with established therapies from Amgen, AstraZeneca, and others generating significant revenue. ALX2004's differentiated mechanism will be a focal point for investors assessing whether the asset can carve out a meaningful niche in a crowded but high-value therapeutic area.

What to watch for during the presentation: any updates on enrollment timelines, preliminary efficacy signals, or partnership discussions around either asset. Management commentary on the competitive positioning of evorpacept relative to other CD47 inhibitors — including lessons from the magrolimab clinical program — would also be closely parsed by the audience.

What ALX Oncology's Conference Slot Means for Investors and BD Teams

ALX Oncology's participation in the Jefferies Global Healthcare Conference provides a structured platform to update the investment community and potential partners on its clinical-stage oncology programs. For BD teams evaluating licensing or co-development opportunities, the fireside chat format typically allows for more candid discussion than a standard slide deck — particularly around clinical timelines, combination strategies, and unmet medical needs the company is targeting.

From an investment standpoint, ALX Oncology trades at a valuation that reflects significant optionality on its pipeline. Any positive clinical readouts or strategic developments communicated at the conference could serve as near-term catalysts. Conversely, a lack of substantive updates may prompt analysts to reassess timelines and probability-adjusted revenue models, particularly for evorpacept, which remains the primary value driver.

The broader context matters too. The Jefferies conference is a key event for evaluating sector-wide trends in healthcare — including M&A appetite, IPO pipeline health, and institutional risk tolerance for clinical-stage oncology names. ALX Oncology's presentation slot places it alongside peer companies at similar stages of development, offering a comparative framework for investors allocating capital across the oncology biotech space.

Frequently Asked Questions

Related coverage

• ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution Reshape Oncology
• Navigating FDA's Clinical Trial Transparency Enforcement: A Practical Guide for Sponsors and Sites Post-April 2026
• ASCO 2026 Preview: Key Data and Trends in Cancer Research